血清乙型肝炎病毒前基因组RNA水平对核苷(酸)类似物初治的慢性乙型肝炎患者疗效预测价值*

doi:10.3969/j.issn.1672-5069.2022.01.006

摘要/Abstract

摘要： 目的探讨应用血清乙型肝炎病毒前基因组RNA(HBV pgRNA)水平预测核苷(酸)类似物初治的慢性乙型肝炎(CHB)患者疗效的价值。方法 2015年8月～2019年12月我院诊治的初始治疗的CHB患者107例,接受恩替卡韦、替诺福韦或替比夫定治疗观察48 w。采用实时荧光定量PCR法检测血清HBV pgRNA,采用ELISA法检测血清HBsAg和HBeAg。应用Logistic回归分析影响疗效的因素,应用MedCalc1 5.1统计学软件绘制ROC,计算曲线下面积(AUC)评价血清HBV pgRNA水平预测核苷(酸)类似物治疗的疗效。结果在治疗48周末,27例(25.2%)患者不应答,另80例(74.8%)患者获得完全应答或部分应答;(完全或部分)应答组血清HBV DNA载量为(6.1±1.0)lg copies/mL,显著低于不应答组【(7.2±1.2) lg copies/mL,P<0.05】,外周血CD4^＋/CD8^＋比值为(0.7±0.2),显著高于不应答组【(0.6±0.1),P<0.05】,血清HBeAg阳性率为41.3%,显著低于不应答组(70.4%,P<0.05),血清HBV pgRNA水平为(5.3±0.8)lg copies/mL,显著低于不应答组【(6.5±1.1)lg copies/mL,P<0.05】;Logistic回归分析显示,基线HBV DNA载量、HBeAg状态和血清HBV pgRNA水平均为影响核苷(酸)类似物治疗的CHB患者疗效的因素(OR=2.793、OR=3.827、OR=4.035,P均<0.05);经ROC分析显示,血清HBV pgRNA水平预测核苷(酸)类似物治疗CHB患者不应答的最佳截断点为5.89 lgcopies/mL,AUC值为0.865(95%CI:0.816～0.905),其预测的灵敏度为74.1%(20/27),特异度为88.8%(71/80)。结论监测血清HBV pgRNA水平预测核苷(酸)类似物初治的CHB患者的疗效有一定的临床应用价值,如果检测结果稳定,不失为一种临床决策的参考依据。

关键词: 乙型肝炎, HBV前基因组RNA, 核苷(酸)类似物, 疗效预测

Abstract: Objective The aim of this study was to explore the predictive value of antiviral response by serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment. Methods 107 naïve patients with chronic hepatitis B (CHB) were enrolled in our hospital between August 2015 and December 2019, and all were treated with nucleos(t)ide analogues, e.g. entecarvir, tenofovir, or telbivodine, for 12 months. Serum HBV pgRNA loads was assayed by real-time fluorescent quantitative PCR, serum HBsAg and HBeAg were detected by ELISA, the multivariate Logistic regression model was applied to analyze the influencing factors of response in CHB patients to nucleos(t)ide analogue treatment, and the area under the receiver operating characteristic curve (AUROC) was applied to predict the antiviral response by serum HBV pgRNA levels in CHB patients receiving nucleos(t)ide analogue treatment. Results At the end of 48 week observation, 27 patients (25.2%) didn't response to antiviral therapy, but 80 patients(74.8%) obtained complete or partial response; serum HBV DNA loads in patients with CR and PR was (6.1±1.0)lg copies/mL, significantly lower than [(7.2±1.2) lg copies/mL, P<0.05], peripheral blood 血CD4^＋/CD8^＋ cell ratio was (0.7±0.2), significantly higher than [(0.6±0.1), P<0.05], serum HBeAg positive rate was 41.3%, significantly lower than (70.4%, P<0.05),and serum HBV pgRNA level was (5.3±0.8)lg copies/mL, significantly lower than [(6.5±1.1)lg copies/mL, P<0.05] in non-responders; the multivariate Logistic regression analysis showed that baseline serum HBV DNA loads, serum HBeAg state and serum HBV pgRNA levels were the independent influencing factors for antiviral response in CHB patients receiving nucleos(t)ide analogue treatment(OR=2.793, OR=3.827, OR=4.035, all P<0.05); the ROC analysis demonstrated that the optimal cut-off-value of serum HBV pgRNA level in predicting response of antiviral therapy in CHB patients was 5.89 lg copies/mL, with the AUC of 0.865(95%CI:0.816-0.905), the sensitivity of 74.1%(20/27) and the specificity of 88.8%(71/80). Conclusion Serum HBV pgRNA levels could be assayed in sera of patients with CHB, and it might be used to predict the antiviral response and warrants further clinical investigation.

Key words: Hepatitis B, Hepatitis B virus pregenomic RNA, Nucleos(t)ide analogues, Response, Prediction

严景全, 王春玲, 刘娟, 卢雪兰, 林占洲, 莫凡. 血清乙型肝炎病毒前基因组RNA水平对核苷(酸)类似物初治的慢性乙型肝炎患者疗效预测价值^*[J]. 实用肝脏病杂志, 2022, 25(1): 22-25.

Yan Jingquan, Wang Chunling, Liu Juan, et al. Predictive value of antiviral response by serum hepatitis B virus pregenomic RNA levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment[J]. Journal of Practical Hepatology, 2022, 25(1): 22-25.

参考文献

[1] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4):1560-1599.
[2] 杨莎莎, 周利. 恩替卡韦联合百令胶囊治疗慢性乙型肝炎患者疗效初步研究. 实用肝脏病杂志, 2018, 21(2):204-207.
[3] Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis b virus infection. Gut liver, 2018,12(5):497-507.
[4] Pan Y, Ke Z, Ye H, et al. Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis. Inflamm Res, 2019, 68(12):1025-1034.
[5] Gu Y, Chen L, Lian Y, et al. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naïve chronic hepatitis B patients. J Med Virol, 2020, 92(3):317-328.
[6] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[7] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63(1):261-283.
[8] Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis b virus infection. Gastroenterology, 2019, 156(2):355-368.
[9] El-Maadawy EA, TalaatRM, Ahmed MM, et al. Interleukin-6 promotor gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Hum Immunol, 2019,80(3):208-214.
[10] 唐平阳, 王洁冰, 张晓兰, 等. 血清HBeAg阴性慢性乙型肝炎患者APRI,FIB-4和血清TGF-β1水平变化. 实用肝脏病杂志 2020, 23(6):801-804.
[11] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol, 2017, 66(2):460-462.
[12] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA, PLoS Pathog, 2020, 16(10):e1008945.
[13] 王颖, 赵奎, 秦建忠. HBV cccDNA, HBsAg, HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值. 临床肝胆病杂志, 2020, 36(5):57-62.
[14] Patel NH, Joshi SS, Lau KCK, et al. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J Clin Virol, 2019, 111(15):42-47.
[15] Liu Y, Feng J, Sun M, et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett, 2019, 454(10):158-170.
[16] Wu S, Luo Y, Viswanathan U, et al. CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging. Antiviral Res, 2018, 159(18):159:1-12.
[17] Li Y, Yao M, Duan X, et al. The USP18 cysteine protease promotes HBV production independent of its protease activity. Virol J, 2020, 17(1):47.
[18] Choi YM, Kim H, Lee SA, et al. A telomerase-derived peptide exerts an anti-hepatitis b virus effect via mitochondrial DNA stress-dependent type i interferon production. Front Immunol, 2020, 11(8):652.
[19] Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat, 2020, 27(3):323-328.
[20] Wu M, Li J, Yue L, et al. Establishment of cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. Antiviral Res, 2018, 152:45-52.
[21] de Rocquigny H, Rat V, Pastor F, et al. Phosphorylation of the arginine-rich c-terminal domains of the hepatitis b virus (HBV) core protein as a fine regulator of the interaction between HBV and nucleic acid. Viruses, 2020, 12(7):738.
[22] Halgand B, Desterke C, Rivière L, et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant. Hepatology, 2018, 67(1):86-96.

血清乙型肝炎病毒前基因组RNA水平对核苷(酸)类似物初治的慢性乙型肝炎患者疗效预测价值^*

Predictive value of antiviral response by serum hepatitis B virus pregenomic RNA levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[2]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[3]	李振, 宁姗姗, 郭影, 王甜甜, 李莉华, 叶美红, 宋源源. 慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 191-194.
[4]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[5]	屈晓威, 冯莉莉, 貌彦昀. 梅毒与梅毒合并病毒性肝炎患者外周血T淋巴细胞亚群变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 34-37.
[6]	中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测[J]. 实用肝脏病杂志, 2021, 24(6): 776-785.
[7]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[8]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.
[9]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[10]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[11]	周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.
[12]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[13]	陈丹丹, 龙志达, 黄顺东, 王文虎, 尹明红, 李忠斌. 慢加急性乙型肝炎肝衰竭患者发生感染和急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 717-720.
[14]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[15]	吴慧, 宋波, 吕承秀, 田文君, 牛家峰. 慢性乙型肝炎患者血清内质网应激指标变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(4): 484-487.